Share-based compensation and stockholders' equity (Tables)

3 Months Ended

Mar. 31, 2024

-based compensation expense, net of forfeitures was recorded in the following financial statement line items:


	Three Months Ended March 31,
	2024		2023
Cost of Commercial Product sales	$	—	$	0.1
Cost of MCM Product sales	0.7		1.3
Cost of Bioservices	0.1		0.3
R&D	0.5		0.7
Selling, general and administrative	4.6		4.4
Total share-based compensation expense	$	5.9	$	6.8

The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:


	Defined Benefit Pension Plan		Derivative Instruments		Foreign Currency Translation Adjustments		Total

Balance at December 31, 2023	$	—	$	—	$	(5.7)	$	(5.7)
Other comprehensive income before reclassifications	—		—		0.2		0.2

Net current period other comprehensive income	—		—		0.2		0.2
Balance at March 31, 2024	$	—	$	—	$	(5.5)	$	(5.5)









Balance at December 31, 2022	$	3.5	$	6.2	$	(6.6)	$	3.1
Other comprehensive loss before reclassifications	—		(4.4)		(0.1)		(4.5)
Amounts reclassified from accumulated other comprehensive income	—		2.4		—		2.4
Net current period other comprehensive loss	—		(2.0)		(0.1)		(2.1)
Balance at March 31, 2023	$	3.5	$	4.2	$	(6.7)	$	1.0

The tables below present the tax effects related to each component of other comprehensive income (loss):


	Three Months Ended March 31,
	2024						2023
	Pretax		Tax Expense		Net of tax		Pretax		Tax Expense		Net of tax

Derivative instruments	—		—		—		(2.6)		0.6		(2.0)
Foreign currency translation adjustments	0.2		—		0.2		(0.1)		—		(0.1)
Total adjustments	$	0.2	$	—	$	0.2	$	(2.7)	$	0.6	$	(2.1)